NanoViricides

NanoViricides reports that its broad-spectrum antiviral drug NV-387 could help reduce metastatic cancer resurgence by preventing viral infections from awakening dormant cancer cells.

NanoViricides has received approval from the Democratic Republic of Congo's National Ethics Committee to proceed with Phase II clinical trials of NV-387 for MPox treatment, addressing a significant unmet need as no effective treatment currently exists.

NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate, as a potential treatment for measles in response to declining vaccination rates and increasing case numbers across the USA.

NanoViricides has completed Phase I clinical trials for NV-387 with no reported adverse events, demonstrating potential as a broad-spectrum antiviral against MPox, RSV, influenza, and COVID-19.

NanoViricides' NV-387 demonstrated an 88% increase in survival rate in animal studies, surpassing existing treatments for influenza, offering a potential solution against H5N1.

NanoViricides is set to advance its broad-spectrum antiviral candidate, NV-387, into Phase II clinical trials, focusing on MPox treatment in Central Africa.

NanoViricides' broad-spectrum antiviral NV-387 is set to advance to Phase II clinical trials, targeting MPOX, RSV, influenza, and COVID-19 infections.

NanoViricides has engaged a CRO to initiate a Phase II clinical trial for NV-387, a broad-spectrum antiviral drug.

NanoViricides is focusing on advancing NV-387, a broad-spectrum antiviral drug, into Phase 2 human clinical trials.

NanoViricides is set to begin Phase II trials for NV-387, an antiviral drug aimed at treating herpes zoster, commonly known as shingles.